This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (Stribild®)

Reference No. 3616

Publication date:

Appraisal information

elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (Stribild®) 150 mg/150 mg/200 mg/245 mg film-coated tablet

Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 06/02/2018

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (Stribild®) cannot be endorsed for use within NHS Wales for the treatment of HIV‑1 infection in adolescents aged 12 to < 18 years weighing ≥ 35 kg who are infected with HIV‑1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild® and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate.
Statement of Advice (SOA)